Purpose: This study aimed to compare the functional and anatomical outcomes of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) injections in patients with neovascular age-related macular degeneration (AMD). Methods:The medical records of 80 AMD patients who received IVR treatment and IVA treatment were assessed.During each visit, best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured.IVR and IVA were administered once per month for three consecutive months, and injections were repeated monthly, as needed, for 1 year.Results: No significant differences were detected between the two groups at baseline and 12-month measurements; CMT decreased by 74.95 μm in IVR group and 74.06 μm in IVA group (p>0.05).In addition, BCVAs in both groups demonstrated an increase of 5.93 letters compared to the baseline (p>0.05).Conclusion: After 1 year, there were no significant differences between groups, in BCVA, CMT, and number of injections with as-needed regimen.
No takes yet. Share an insight, caveat, or question.
Perente et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: